Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Thoracic 4Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ALT-803 × Gastrointestinal × 90 days × Clear all
NCT06149481 2026-06-05

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07488884 2026-04-29

ResQ108B-PANC

ImmunityBio, Inc.

Phase 1 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡